Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Dean Capital Management

Dean Capital Management grew its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,492 shares of the specialty pharmaceutical company’s stock after buying an additional 366 shares during the period. Dean Capital Management’s holdings in Jazz Pharmaceuticals were worth $2,047,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Versant Capital Management Inc boosted its holdings in shares of Jazz Pharmaceuticals by 9.4% in the 1st quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 91 shares in the last quarter. Kendall Capital Management boosted its holdings in shares of Jazz Pharmaceuticals by 1.2% in the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company’s stock valued at $989,000 after buying an additional 95 shares in the last quarter. Louisiana State Employees Retirement System boosted its holdings in shares of Jazz Pharmaceuticals by 0.6% in the 1st quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company’s stock valued at $2,098,000 after buying an additional 100 shares in the last quarter. Sound View Wealth Advisors Group LLC boosted its holdings in shares of Jazz Pharmaceuticals by 1.3% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company’s stock valued at $1,046,000 after buying an additional 110 shares in the last quarter. Finally, Cardinal Capital Management boosted its stake in Jazz Pharmaceuticals by 0.9% during the 1st quarter. Cardinal Capital Management now owns 13,254 shares of the specialty pharmaceutical company’s stock worth $1,645,000 after purchasing an additional 114 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Up 0.3%

JAZZ stock opened at $129.85 on Tuesday. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06. The stock has a market capitalization of $7.88 billion, a PE ratio of -19.29, a price-to-earnings-growth ratio of 8.03 and a beta of 0.24. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The company has a fifty day moving average of $117.16 and a 200-day moving average of $116.73.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same quarter last year, the business posted $5.30 EPS. The firm’s revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the sale, the director owned 429,973 shares in the company, valued at $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.30% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on JAZZ. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a “buy” rating and a $152.00 price target for the company. Wall Street Zen cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 15th. Truist Financial increased their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Fourteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $178.67.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.